Stock Events

Stock Events

Bio-Path 

€0
69
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7MarExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-4.51
-3.13
-1.74
-0.35
Expected EPS
-0.3526655
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-17.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IBP0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Bio-Path's nucleic acid-based treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap12.1B
Ionis Pharmaceuticals specializes in antisense technology, which is a direct competitor to Bio-Path's DNA/RNA-based drug development.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.35B
Arrowhead Pharmaceuticals develops drugs based on RNA interference, competing in the same space as Bio-Path's RNA-based therapies.
Moderna
MRNA
Mkt Cap20.12B
Moderna is a leader in mRNA technology, which is a form of nucleic acid therapy competing with Bio-Path's own DNA/RNA-based treatments.
BioNTech
BNTX
Mkt Cap26.67B
BioNTech SE, known for its mRNA-based vaccines, competes in the broader nucleic acid therapy space alongside Bio-Path.
Sarepta Therapeutics
SRPT
Mkt Cap2.13B
Sarepta Therapeutics focuses on RNA-targeted therapeutics, particularly in genetic medicine, competing with Bio-Path's genetic intervention strategies.
CRISPR Therapeutics
CRSP
Mkt Cap4.7B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of genetic medicine that competes with Bio-Path's gene-based therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.61B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, directly competing with Bio-Path's focus on genetic diseases.

About

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Show more...
CEO
ISIN
US09057N4097
WKN
000A403XM

Listings

OTC Link
US
BPTH

0 Comments

Share your thoughts

FAQ

What is Bio-Path stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bio-Path stocks are traded under the ticker IBP0.F.
What is Bio-Path revenue for the last year?▼
Bio-Path revenue for the last year amounts to 0 EUR.
What is Bio-Path net income for the last year?▼
IBP0.F net income for the last year is -17.83M EUR.
In which sector is Bio-Path located?▼
Bio-Path operates in the Other sector.
When did Bio-Path complete a stock split?▼
The last stock split for Bio-Path was on February 23, 2024 with a ratio of 1:20.